Market News
Smart Trading. Simplified.
Small Biotech Could Soar 1,000%
There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks.
In the past year alone...
Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
Here's the next biotech we think could soar 1,000% >>>
Sponsored
5 Top Video Game Stocks To Buy
The video games industry was already a massive industry, but this past year has created a perfect storm for industry growth. With everyone stuck at home and businesses closed, the only way for many people to get any action is through gaming. Over $29.4 billion in video games were sold through September, before the latest […]
Tiny Massachusetts Company Awarded $75 Billion Patent
Tiny biotech's breakthrough proves it's possible to remove cancer cells from sick patients. Bill Gates says new discovery is so powerful it could "help humanity." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $1.57 Million >>>
Sponsored
Investing vs Gambling: What Is The Difference?
The Reddit-fueled stock market rallies in 2020 bring an important question back to the table. On the surface, investing in the stock market can feel a lot like gambling. You risk some capital and hope for more in return. However, there are some key differences between investing vs gambling. It certainly can feel like sitting […]
My #1 Small Cap Stock for March
Ex-Wall Street CEO Dylan Jovine has racked up big gains in small caps stocks. He's had three picks jump 100%, 111% and 171% just in the past 90 days!
Sponsored
3 Top Insurance Stocks To Buy
Insurance is a long-standing industry for a reason. Disasters happen, and insurance companies underwrite policies to protect people against catastrophic losses. Whether it’s your health, life, house, car, or even your pet, there’s a good chance an agent can find a policy to cover you. These companies earn their money by charging customers monthly and […]
Small Biotech Could Soar 1,000%
On December 5, 2020, a small Cambridge biotech shocked the world when they could "Find & Replace" the genes that cause the disease anemia. Investor's Business Daily estimates the total market at $75 billion. But right now, its stock is just a tiny fraction of that size.
Here's the next biotech we think could soar 1,000% >>>
Sponsored
Is Upstart Stock A Buy?
Traditional banking was one of the first areas in which tech entrepreneurs made bold, dramatic moves to disrupt the industry. Banking was complicated, expensive, and out of reach for many consumers, leaving them open to predatory lending practices. The industry was ripe for change, as too few people had access to the information and tools […]
Stock Market Whiz Kid Works 1 Hour a Day. Makes Millions.
He was living with his parents. Two years later he had $5 million to play with - all because of this 1 EXTRA INCOME strategy.
To see how he did it click here.
Sponsored
Is Vuzix Stock A Buy?
Is Vuzix Stock A Buy? Vuzix (VUZI) is the pre-eminent brand in enterprise-focused augmented reality smart-glasses. The company has a strong market presence in multiple industrial and healthcare sectors, and is also developing a consumer product for roll-out further down the line. The firm both designs and makes its own self-contained augmented reality products, and […]
New 5G "Arrow" to Replace Nuclear Missiles
On August 30, 2019, a small firm won a contract from the Pentagon to build a strange new weapon. The New York Times reports "No existing defense can stop it." This under-the-radar company is not yet a household name.
Our research proves that anyone who gets in now could turn $1,000 into $461,800 >>>
Sponsored
View this email online if it doesn't display correctly. This newsletter is not financial advice. Please read our Disclaimer.
To unsubscribe from Financhill, click here.
Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.
The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.
The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The Financhill.com educational training program and software services are provided to improve financial understanding.
The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.
Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.
No comments:
Post a Comment